Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Actinogen Medical ( (AU:ACW) ) has provided an announcement.
Actinogen Medical has received approval for an Advance Overseas Finding, allowing them to claim an additional $1.9 million in research and development tax incentives for the 2025 financial year. This approval increases their total RDTI rebate to over $7.3 million, which will support their ongoing Alzheimer’s phase 2b/3 clinical trial. The trial is a significant step in their efforts to develop Xanamem as a treatment for Alzheimer’s, with interim results expected in January 2026 and final results in late 2026. This financial boost is crucial as the company approaches key milestones in its clinical trials, potentially strengthening its position in the biotechnology industry and offering hope for stakeholders looking for advancements in Alzheimer’s treatment.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease, Depression, and potentially other conditions like Fragile X Syndrome. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and neuropsychological burdens associated with these diseases.
YTD Price Performance: 20.0%
Average Trading Volume: 2,595,143
Technical Sentiment Signal: Hold
Current Market Cap: A$95.26M
Learn more about ACW stock on TipRanks’ Stock Analysis page.